- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00445809
Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury (EVOLVE)
EValuation Of NGAL in Early and eVolving Acute kidnEy Injury
Visão geral do estudo
Status
Condições
Descrição detalhada
Approximately 350 adults scheduled to undergo cardiac surgery involving the use of cardiopulmonary bypass will be enrolled. Blood samples will be obtained from all patients in the study for future measurement of both plasma NGAL and plasma creatinine levels in the same sample at each of nine time points.
Blood samples for later assessment using the Triage NGAL Test will be processed to plasma at the clinical site, frozen and shipped to Biosite for storage. Testing with the Triage NGAL Test will be conducted at Biosite by trained laboratory personnel. The results of these assessments will be blinded to the medical team during the study and will not impact the medical management of the patient.
The medical team caring for each study patient should obtain clinical laboratory tests per their usual post-operative routine and manage the patient accordingly. Any serum creatinine measurements obtained by the site as part of this routine care both pre-operatively and through Day 10 post-operatively will be recorded as well as any additional post-operative renal insults, the development of oliguria, the need for a nephrology consultation, initiation of dialysis and mortality will also be recorded through Day 10.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
British Columbia
-
Vancouver, British Columbia, Canadá
- University of British Columbia
-
-
-
-
Colorado
-
Denver, Colorado, Estados Unidos
- St. Anthony's Central Hospital
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos
- George Washington University
-
-
Maine
-
Portland, Maine, Estados Unidos
- Maine Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Estados Unidos
- Massachusetts General Hospital
-
-
New York
-
Albany, New York, Estados Unidos
- St. Peters Healthcare
-
Brooklyn, New York, Estados Unidos
- New York Methodist
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos
- Cleveland Clinic Foundation
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos
- University of Pittsburgh
-
-
Texas
-
Houston, Texas, Estados Unidos
- University of Texas, Houston
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
4.2.1 Inclusion Criteria
- Male or female scheduled for cardiovascular surgery (other than cardiac transplant) requiring cardiopulmonary bypass
- 18 years of age or older
i. The first approximately 150 to200 patients enrolled must have:
• A Prediction of Acute Renal Failure Score ≥ 5 (see Reference 18 and Appendix B)
ii. The subsequent patients enrolled must have one or more of the following risk factors for post-bypass renal injury:
- Age > 70;
- Pre-operative creatinine > 1.4 mg/dL;
- NYHA Class 3 or 4 heart failure or left ventricular ejection fraction < 35%;
- Insulin-dependent diabetes mellitus;
- Undergoing cardiac valve surgery;
- History of previous cardiac surgery.
Exclusion Criteria:
- Age < 18 years
- Inability to obtain Informed Consent from patient or representative
- Prisoners or other institutionalized or vulnerable individuals
- Participation in an interventional clinical study within the previous 30 days
- History of previous renal transplantation
- Stage 5 chronic kidney disease (estimated GRF<15 mL/min/1.73m2) (See Appendix C)
- Known or suspected ongoing pre-operative acute renal failure due to any cause, including pre-renal, intrinsic renal or post-renal (obstructive) etiologies (as evidenced by increasing serum creatinines or oliguria pre-operatively)
- Already receiving dialysis, in imminent need of dialysis or considered highly likely to need dialysis in the immediate post-operative period for fluid management
- Any known or suspected renal ischemic insult(such as cardiac arrest)or nephrotoxic insult(other than intravascular contrast procedure) during the 48 hours prior to surgery
- Known or suspected infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV)infection, hepatitis B virus (HBV) infection or other infectious hepatitis
- Pre-operative hematocrit <25%, recent blood transfusions have been administered to maintain hematocrit >25% or any other contraindication to obtaining the study-specified blood samples
- Undergoing cardiac transplantation
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: Coorte
- Perspectivas de Tempo: Prospectivo
Coortes e Intervenções
Grupo / Coorte |
---|
1
High Risk population for developing AKI during/after CABG surgery.
|
2
Medium Risk population for developing AKI during/after CABG surgery.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Emil Paganini, MD, The Cleveland Clinic
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- BSTE-0401
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .